 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--- KALV--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 HAE International HAEi Global Leadership Workshop taking place in Frankfurt, Germany from October 6-9. The presentations are: Patient Perspectives on an Optimal Outcome Measure to Ass 